IBDEI0QO ; ; 12-AUG-2014
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,13160,1,5,0)
 ;;=5^Personal h/o Lung Cancer
 ;;^UTILITY(U,$J,358.3,13160,2)
 ;;=^295211
 ;;^UTILITY(U,$J,358.3,13161,0)
 ;;=V10.79^^87^830^59
 ;;^UTILITY(U,$J,358.3,13161,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,13161,1,4,0)
 ;;=4^V10.79
 ;;^UTILITY(U,$J,358.3,13161,1,5,0)
 ;;=5^Personal h/o Lymphoma
 ;;^UTILITY(U,$J,358.3,13161,2)
 ;;=^295238
 ;;^UTILITY(U,$J,358.3,13162,0)
 ;;=V10.02^^87^830^65
 ;;^UTILITY(U,$J,358.3,13162,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,13162,1,4,0)
 ;;=4^V10.02
 ;;^UTILITY(U,$J,358.3,13162,1,5,0)
 ;;=5^Personal h/o Oral Cavity/Pharynx Cancer
 ;;^UTILITY(U,$J,358.3,13162,2)
 ;;=^295204
 ;;^UTILITY(U,$J,358.3,13163,0)
 ;;=V10.06^^87^830^71
 ;;^UTILITY(U,$J,358.3,13163,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,13163,1,4,0)
 ;;=4^V10.06
 ;;^UTILITY(U,$J,358.3,13163,1,5,0)
 ;;=5^Personal h/o Rectal/Anal Cancer
 ;;^UTILITY(U,$J,358.3,13163,2)
 ;;=^295208
 ;;^UTILITY(U,$J,358.3,13164,0)
 ;;=V10.52^^87^830^72
 ;;^UTILITY(U,$J,358.3,13164,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,13164,1,4,0)
 ;;=4^V10.52
 ;;^UTILITY(U,$J,358.3,13164,1,5,0)
 ;;=5^Personal h/o Renal Cancer
 ;;^UTILITY(U,$J,358.3,13164,2)
 ;;=^295229
 ;;^UTILITY(U,$J,358.3,13165,0)
 ;;=V10.04^^87^830^75
 ;;^UTILITY(U,$J,358.3,13165,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,13165,1,4,0)
 ;;=4^V10.04
 ;;^UTILITY(U,$J,358.3,13165,1,5,0)
 ;;=5^Personal h/o Stomach Cancer
 ;;^UTILITY(U,$J,358.3,13165,2)
 ;;=^295206
 ;;^UTILITY(U,$J,358.3,13166,0)
 ;;=V10.47^^87^830^78
 ;;^UTILITY(U,$J,358.3,13166,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,13166,1,4,0)
 ;;=4^V10.47
 ;;^UTILITY(U,$J,358.3,13166,1,5,0)
 ;;=5^Personal h/o Testicular Cancer
 ;;^UTILITY(U,$J,358.3,13166,2)
 ;;=^295225
 ;;^UTILITY(U,$J,358.3,13167,0)
 ;;=V08.^^87^830^32
 ;;^UTILITY(U,$J,358.3,13167,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,13167,1,4,0)
 ;;=4^V08.
 ;;^UTILITY(U,$J,358.3,13167,1,5,0)
 ;;=5^HIV + Status (Asymptomatic)
 ;;^UTILITY(U,$J,358.3,13167,2)
 ;;=^303392
 ;;^UTILITY(U,$J,358.3,13168,0)
 ;;=V07.4^^87^830^33
 ;;^UTILITY(U,$J,358.3,13168,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,13168,1,4,0)
 ;;=4^V07.4
 ;;^UTILITY(U,$J,358.3,13168,1,5,0)
 ;;=5^Hormone Replacement Therapy
 ;;^UTILITY(U,$J,358.3,13168,2)
 ;;=^331975
 ;;^UTILITY(U,$J,358.3,13169,0)
 ;;=V13.59^^87^830^63
 ;;^UTILITY(U,$J,358.3,13169,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,13169,1,4,0)
 ;;=4^V13.59
 ;;^UTILITY(U,$J,358.3,13169,1,5,0)
 ;;=5^Personal h/o Musculoskletl Dis
 ;;^UTILITY(U,$J,358.3,13169,2)
 ;;=^295268
 ;;^UTILITY(U,$J,358.3,13170,0)
 ;;=V12.51^^87^830^45
 ;;^UTILITY(U,$J,358.3,13170,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,13170,1,4,0)
 ;;=4^V12.51
 ;;^UTILITY(U,$J,358.3,13170,1,5,0)
 ;;=5^Personal h/o DVT
 ;;^UTILITY(U,$J,358.3,13170,2)
 ;;=^303397
 ;;^UTILITY(U,$J,358.3,13171,0)
 ;;=V11.2^^87^830^46
 ;;^UTILITY(U,$J,358.3,13171,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,13171,1,4,0)
 ;;=4^V11.2
 ;;^UTILITY(U,$J,358.3,13171,1,5,0)
 ;;=5^Personal h/o Dysthymia
 ;;^UTILITY(U,$J,358.3,13171,2)
 ;;=^295251
 ;;^UTILITY(U,$J,358.3,13172,0)
 ;;=V13.01^^87^830^54
 ;;^UTILITY(U,$J,358.3,13172,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,13172,1,4,0)
 ;;=4^V13.01
 ;;^UTILITY(U,$J,358.3,13172,1,5,0)
 ;;=5^Personal h/o Kidney Stone
 ;;^UTILITY(U,$J,358.3,13172,2)
 ;;=^303403
 ;;^UTILITY(U,$J,358.3,13173,0)
 ;;=V10.61^^87^830^58
 ;;^UTILITY(U,$J,358.3,13173,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,13173,1,4,0)
 ;;=4^V10.61
 ;;^UTILITY(U,$J,358.3,13173,1,5,0)
 ;;=5^Personal h/o Lymphoid Leukemia
 ;;^UTILITY(U,$J,358.3,13173,2)
 ;;=^295232
